Merck To Sign 50 Business Development Deals In 2005
Executive Summary
Merck's goal is to sign about 50 business development deals in 2005, the same level as 2004, the company said
You may also be interested in...
Merck’s Licensing Philosophy Mixes Acquisitions And Development Deals
Merck is bolstering its pipeline through acquisitions and licensing deals, many in biotech. The drug maker evaluates 6,000 opportunities per year and signed 44 transactions in 2005, in line with its projections of about 50 deals (1"The Pink Sheet" Jan. 10, 2005, p. 35). Merck VP & Chief Licensing Officer Barbara Yanni recently sat down with "The Pink Sheet" DAILY to outline the company's licensing strategy and talk about plans for future growth.
Merck To Increase Internal R&D But Reduce Outside Deals In 2005
Merck expects to decrease its spending on product acquisition and licensing deals in 2005, the company told analysts during its Dec. 14 annual business review in Whitehouse Station, N.J
Merck Sees Slightly More Success With External Rx Than Internal Candidates
Merck has a slightly higher success rate with drug candidates developed through external licensing deals than with internally discovered compounds, Merck Senior Director-Strategic Research Initiatives, External Scientific Affairs Ronald Newbold said